Affordability of effective and innovative medications within the current Canadian public funding model is becoming very challenging for the healthcare system. Increasing budgetary constraints coupled with complex treatments requiring consideration of different sources and levels of evidence are an issue for all stakeholders. To help address this increasingly difficult environment, MORSE Consulting has bolstered its health technology assessment (HTA) and payer expertise.
We now offer HTA strategic advice through the addition of Anita Carrie, a senior consultant who has more than 20 years of experience working in multiple sectors including HTA, hospital and consulting sectors. Most recently Anita served as a scientific advisor and research manager at Canadian Agency for Drugs and Technologies in Health (CADTH). During her time at CADTH Anita led or conducted the review of more than 100 single technology reviews, including communicating reimbursement recommendations of expert committees to public drug plans and other stakeholders. She is also a former practicing pharmacist, educator, and health services researcher experienced in conducting real world studies using administrative healthcare data.
Given the increasing linkages and coordination between different elements of the Canadian reimbursement pathway, it is imperative to understand the impact of HTA recommendations on payer negotiations and listing criteria. Anita’s extensive CADTH experience, both as a scientific advisor and research manager, combined with MORSE’s public payer expertise will help our clients better understand and optimize their reimbursement planning and decision-making.
As a Senior Consultant, Anita is responsible for providing substantive guidance to clients related to MORSE’s reimbursement and health technology assessment strategy services.
MORSE Consulting is also pleased to further strengthen our public payer expertise through the addition of our new senior consultant, Roy Cairns. He is a pharmacist with 35 years of experience and has represented a public payer at the assistant deputy minister (ADM), executive director, and operational levels and worked with federal/provincial/territorial governments, private insurers, pharmacy wholesalers, retail pharmacies, and pharmaceutical manufacturers. Roy has represented a jurisdiction at the Canadian Agency for Drugs and Technologies in Health (CADTH), through both the oncology and non-oncology streams, as well as the pan-Canadian Pharmaceutical Alliance (pCPA) – at all levels including the Governing Council. Roy has also participated in numerous national initiatives involving federal organizations (e.g. Health Canada, the Patented Medicine Prices Review Board) on topics such as National Pharmacare, Biologics/Biosimilars, and Expensive Drugs for Rare Diseases.
Beyond his understanding of regional issues, Roy’s involvement spans across jurisdictional, executive and operational frameworks that provides a unique perspective on how drug policy is developed and implemented in Canada.
As a Senior Consultant, Roy contributes to client success by providing public payer insights from numerous decision-making perspectives to better inform product positioning, pricing, reimbursement, and negotiation strategies.
The addition of Anita and Roy will further strengthen MORSE’s ability to provide clients with insightful strategies to help them effectively address Canada’s challenging and rapidly evolving reimbursement environment.